The Efficacy and Safety of Pembrolizumab in Anaplastic Thyroid Carcinoma: A Systematic Review and Meta‐Analysis
Authors' conclusion
Our meta-analysis showed that Pembrolizumab has potential antitumor implications in ATC and is extremely well tolerated.
Study context
- Population
- Patients with ATC; studies from PubMed, EMBASE and Cochrane Library8 studies
- Outcome
- Main outcomes: ORR, SD, DCR, mOS and AEs
Pooled result
As reported in the abstract
Pooled objective response rate (ORR)
46.0%
Pooled SD
20%
Pooled disease control rate (DCR)
74%
Pooled median overall survival (mOS)
9.62 months
Safety
- Incidence of grade ≥ 3 adverse events (AEs) significantly lower, rarely exceeding
- 5%
- Most patients had grade 1 or 2 AEs
Original publication
The Efficacy and Safety of Pembrolizumab in Anaplastic Thyroid Carcinoma: A Systematic Review and Meta‐Analysis. Clin Endocrinol (Oxf). Published 15 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →